Marijuana Consumers Overwhelmingly Back Trump’s Rescheduling Order, Poll Shows As Advocates Await DOJ Action

Marijuana rescheduling poll: the people who actually inhale the smoke and taste the resin say it’s time. A new survey of consumers shows overwhelming support for President Trump’s executive order directing the attorney general to push cannabis from Schedule I to Schedule III—an overdue jailbreak from the prohibition-era attic where curiosity and commerce go to die. It’s not legalization. Not yet. But in the gritty trench warfare of cannabis policy reform, this rescheduling order could be the difference between crawling and finally standing upright. The core message from the cannabis market is simple: move, don’t muse. Consumers want federal clarity, tax sanity, and a research pipeline unclogged of bureaucratic hairballs. That’s the headline and the heartbeat, and it sets the table for how the Michigan-and-Maine, Missouri-and-Montana patchwork becomes a national story about economic opportunity, public health data, and a government finally catching up to reality.

The poll is blunt about it. Eighty-three percent of respondents back the executive order to reschedule marijuana, with only a sliver opposed and a small shrugging middle. These aren’t armchair pundits; they’re people who buy, dose, microdose, and navigate the dispensary aisles that have replaced street corners. Asked about the practical stakes—like opening the door to real medical research and freeing businesses from the 280E tax vise that treats them like hustlers while demanding they act like hospitals—nearly three in four said they care a great deal. That’s the cannabis industry impact that matters: the prospect of Schedule III marijuana pulling the plug on punitive tax treatment and letting operators reinvest in compliance, wages, and safer products instead of watching margins bleed out. Think of it as moving from a back-alley window to a front-of-house ledger—same plant, different universe. More labs, more trials, more data. Fewer whispers, more receipts.

But the nation’s capital is a town built on hurry-up-and-wait. Despite the executive order’s drumbeat—“expeditious” is the word—the Department of Justice hasn’t thrown the switch. Rumors swirl, and alphabet-soup agencies keep their poker faces. Somewhere between legal memos and administrative process, there’s talk of draft rules, appeals still pending, and whether a new filing would slow-walk what’s already teed up. Welcome to federal rulemaking, where the gears grind so slowly you start tasting metal. The stakes are enormous: rescheduling would still leave adult-use state markets operating outside formal FDA pathways, but it could normalize banking, accelerate clinical studies, and yank businesses out of the tax penalty box. Politically, it’s a live wire. One camp sees the order as the strongest nudge yet; skeptics eye the Justice Department’s silence and wonder if the can is about to be kicked again. In the middle sit millions of patients and consumers, waiting for the government to acknowledge what dispensary receipts and public opinion have been saying for years.

Meanwhile, the states continue to cook their own dishes, spice levels varying wildly. In Kentucky, the governor’s office says the medicating public can finally reach for edibles, as in Kentucky Governor Announces Medical Marijuana Gummies Are Now Available, While Pushing Lawmakers To Approve New Qualifying Conditions. In Wisconsin, a cautious, GOP-scripted step forward limps alongside louder calls to go broader, captured in Wisconsin Senators Approve GOP-Led Medical Marijuana Bill As Democrats Push Broader Recreational Legalization. In Mississippi, compassion is meeting the hospital corridor for those with no time left to argue, reflected in Mississippi House Approves Bill To To Allow Medical Marijuana Use In Hospitals For Terminally Ill Patients. And in the Rockies, cannabis rights crash headlong into Second Amendment orthodoxy, forcing a blue-state leader to cross his own wires, as in Colorado Governor Is ‘Pushing Back’ Against His Own State’s Position Supporting Federal Gun Ban For Marijuana Consumers. Patchwork is the polite word. What it really looks like is a hundred cooks fighting over the same burner while the feds hold the gas line.

So what happens if DOJ finally moves and cannabis lands in Schedule III? Expect immediate fights over how quickly Section 280E relief hits balance sheets. Expect a research boom—real clinical trials, not just anecdotes, on pain, sleep, anxiety, and the dozens of conditions patients already treat in the shadows of legitimacy. Expect supply chains to rethink compliance and auditing as pharmacies, physicians, and payers sniff around the edges. And expect pushback: lawsuits, amendments, and last-ditch efforts to keep the status quo dressed up as prudence. This is how the sausage gets made. It’s messy. It’s political. It’s late-night, neon-lit, and it will test the patience of every entrepreneur and patient who’s been told “soon” for a decade. Still, that poll is more than a data point; it’s a map with a thick arrow pointing forward. When Washington is done circling the runway, consumers and operators will be ready to land—until then, if you’re looking for a clean, curated place to explore the plant’s possibilities, take a slow walk through our shop at https://thcaorder.com/shop/.